IQVIA Holdings Inc. Common Stock (IQV)
Stock · NYSE · Health Care
$266.89as of 10/16/2026
Price chart
Active signals
IQV Signal Track Record
How signals performed across all stocks →What IQV's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 32 | +2.5% | 56% | September 16, 2026 |
| Bollinger Band Breakdown | 23 | -0.2% | 48% | April 23, 2026 |
| Bollinger Band Breakout | 22 | +3.5% | 64% | August 21, 2026 |
| 200-Day Moving Average TouchActive now | 20 | -1.0% | 45% | July 22, 2026 |
| Any 20-session window (baseline) | +0.3% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IQV
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud…
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Employees
- 94,000
- Website
- ir.iqvia.com/
Fundamentals
- 1-day range
- $267.48$272.98
- Market cap
- $38.26B
- P/E (trailing)
- 32.32
- P/E (forward)
- 18.55
- EPS (trailing)
- $8.07
- Dividend yield
- —
- Beta
- 1.18
- Avg. volume
- 1.46M
How IQVIA Holdings Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 17, 2026 · via SEC EDGAR / Finnhub
Forecasts
19 analyst ratings
IQVIA Holdings Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IQVIQVIA Holdings Inc. Common Stock$266.9▼ 1.53%Market cap $38.26BP/E 32.32$154.5$277.4
- INCYIncyte Corp. Common Stock$113.07▼ 0.18%Market cap $24.00BP/E 14.30$84.02$132.6
- MEDPMedpace Holdings Inc. Common Stock$618.47▼ 1.61%Market cap $16.33BP/E 35.88$373$677.9
- CRLCharles River Laboratories International Inc. Common Stock$300.15▼ 1.99%Market cap $12.79BP/E —$146.2$333.3
- ICLRICON plc Ordinary Shares$170.18▼ 2.83%Market cap $12.34BP/E 190.41$66.57$203.91
- ABSIAbsci Corporation Common Stock$8.25▼ 7.09%Market cap $1.29BP/E —$2.24$12.06
- NRCNRC Health Common Stock$20.15▼ 4.55%Market cap $430.67MP/E 79.70$11.01$23.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IQV IQVIA Holdings Inc. Common Stock | $38.26B | 32.32 | $266.9 | ▼ 1.53% | $154.5$277.4 |
| INCY Incyte Corp. Common Stock | $24.00B | 14.30 | $113.07 | ▼ 0.18% | $84.02$132.6 |
| MEDP Medpace Holdings Inc. Common Stock | $16.33B | 35.88 | $618.47 | ▼ 1.61% | $373$677.9 |
| CRL Charles River Laboratories International Inc. Common Stock | $12.79B | — | $300.15 | ▼ 1.99% | $146.2$333.3 |
| ICLR ICON plc Ordinary Shares | $12.34B | 190.41 | $170.18 | ▼ 2.83% | $66.57$203.91 |
| ABSI Absci Corporation Common Stock | $1.29B | — | $8.25 | ▼ 7.09% | $2.24$12.06 |
| NRC NRC Health Common Stock | $430.67M | 79.70 | $20.15 | ▼ 4.55% | $11.01$23.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- IQVIA Expands Partnership Veeva Systems On Enterprise Standard Applications That Will Be Used Across IQVIA Clinical Development Studiesbenzinga · 10/13/2026
- IQVIA Holdings (IQV) Prices $2b Notes, Does The Stock Look Fairly Valued?Yahoo · 9/19/2026
- IQVIA (IQV) Stock Could Be Undervalued After Its 42% RunYahoo · 9/19/2026
- 5 Undervalued Oncology Stocks Wall Street Is OverlookingSeekingAlpha · 9/18/2026
- Morgan Stanley Maintains Equal-Weight on IQVIA Holdings, Raises Price Target to $270Benzinga · 9/17/2026
- IQVIA Stock Rises 60% in 6 Months: Here's What You Should KnowYahoo · 9/16/2026
- A Strong Rebound Case of IQVIA Holdings (IQV)Yahoo · 9/15/2026
Insider Activity
Insider Actions →- STAUB W RICHARD · August 3, 2026 · Sale5.5K @ $232.68
- Patel Bhavik · July 31, 2026 · Sale1.9K @ $235.27
- Sherbet Eric · July 29, 2026 · Sale5.0K @ $249.16
- Cherofsky Keriann · July 29, 2026 · Sale558 @ $245.21
- BOUSBIB ARI · July 29, 2026 · Option Exercise156.2K @ $78.21
- BOUSBIB ARI · July 29, 2026 · Disposition2.1K @ $247
- BOUSBIB ARI · July 29, 2026 · Disposition47.9K @ $244.6
- BOUSBIB ARI · July 29, 2026 · Sale53.2K @ $244.78
- BOUSBIB ARI · July 29, 2026 · Sale44.0K @ $246.08
- BOUSBIB ARI · July 29, 2026 · Sale4.6K @ $246.85
- BOUSBIB ARI · July 29, 2026 · Sale4.5K @ $247.1
- Wims Morris Leslie · July 14, 2026 · Grant148 @ $207.83
- Fasano Jim · July 14, 2026 · Grant195 @ $207.83
- GOGGINS COLLEEN A · July 14, 2026 · Grant183 @ $207.83
- DANHAKL JOHN G · July 14, 2026 · Grant160 @ $207.83
Institutional Ownership
March 31, 2026
- Total shares held
- 142.73M
- Total value held
- $23.67B
- Institutional holders
- 1055
- Unknown15.03M
- Unknown12.18M
- Unknown11.03M
- Unknown7.48M
- Unknown5.06M
- Unknown4.46M
- Unknown4.24M
- Unknown3.26M
- Unknown2.88M
- Unknown2.61M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IQVIA Expands Veeva Partnership and Raises Price Targets
IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.
IQVIA Expands Veeva Partnership and Raises Price Targets. IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.